Background: Transcatheter aortic valve replacement (TAVR) has emerged as the preferred treatment for patients with severe aortic stenosis across all surgical risk categories. However, outcomes data in patients with prior surgical aortic valve replacement (SAVR) remain limited... The valve-in-valve (ViV) approach using TAVR presents unique anatomic and hemodynamic considerations, including the risk of patient-prosthesis mismatch and coronary obstruction. This registry analysis examines 30-day and 1-year outcomes across 14 high-volume centers, seeking to define procedural benchmarks and identify patient subgroups most likely to benefit from ViV-TAVR versus redo-SAVR.

Background: The SGLT2 inhibitor class has rapidly transformed the management of heart failure, demonstrating consistent benefits in reducing hospitalizations and cardiovascular mortality. Recent landmark trials have expanded the evidence base to include patients with preserved ejection fraction... This comprehensive review synthesizes mechanistic data — encompassing natriuresis, cardiorenal interactions, and mitochondrial effects — alongside trial evidence from EMPEROR-Preserved and DELIVER. We address practical prescribing considerations, including patient selection, drug interactions, and monitoring parameters relevant to the outpatient cardiology setting.

Background: The ISCHEMIA trial fundamentally challenged the paradigm of routine revascularization in stable ischemic heart disease. Extended follow-up data have further nuanced our understanding, yet the translation of these findings into clinical practice remains inconsistent... This critical appraisal examines the trial methodology, baseline characteristics, and outcome definitions that shape the generalizability of ISCHEMIA's conclusions. We explore how subgroup interactions — particularly among patients with diabetes, left ventricular dysfunction, and high ischemic burden — inform a more individualized approach to revascularization counseling.